“This is an exciting time for Syndax as we transition to a commercial stage company,” said Michael A. Metzger, Chief Executive Officer. “We’ve made significant progress advancing our pipeline this quarter, including the presentation of updated revumenib combination data from the BEAT AML and AUGMENT-102 trials and additional axatilimab data from the AGAVE-201 trial at EHA. We are excited to continue building on this momentum as we look ahead to the approval of both first-in-class assets and sharing pivotal AUGMENT-101 data in mNPM1 AML this year.” The company continues to believe it has sufficient capital to fund its research, clinical development and commercial operations through 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
- Syndax announces PDUFA action date extension for revumenib NDA
- Syndax participates in a conference call with JPMorgan
- Syndax granted orphan status for leukemia treatment
- Syndax initiated with a Buy at Jefferies